Jeffrey W. Winkelman

Corporate Officer/Principal at POSEIDA THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

Jeffrey W.
Winkelman is currently the Chief Patent Counsel & Senior Vice President at Poseida Therapeutics, Inc. He previously worked as the Vice President-Intellectual Property & Contracts at ANI Pharmaceuticals, Inc. He holds a doctorate degree from the University of California, Irvine and a graduate degree from the University of San Diego.

Jeffrey W. Winkelman active positions

Companies	Position	Start
POSEIDA THERAPEUTICS, INC.	Corporate Officer/Principal	01/10/2019

All active positions of Jeffrey W. Winkelman

Former positions of Jeffrey W. Winkelman

Companies	Position	End
Elitra Pharmaceuticals, Inc. Elitra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Elitra Pharmaceuticals, Inc. used to develop pharmaceutical products. The company employed proprietary methods for gene analysis and anti-microbial drug discovery. It used to develop technology to miniaturize anti-microbial drug screens. It was also engaged in the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. The company was founded in 1997 and was headquartered in San Diego, CA	Corporate Officer/Principal	-
MIRATI THERAPEUTICS	Corporate Officer/Principal	-
Cell Genesys, Inc. Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.	Corporate Officer/Principal	-
ANI PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

See the detail of Jeffrey W. Winkelman's experience

Training of Jeffrey W. Winkelman

University of California, Irvine	Doctorate Degree
University of San Diego	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jeffrey W. Winkelman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ANI PHARMACEUTICALS, INC.	Health Technology
POSEIDA THERAPEUTICS, INC.	Health Technology

Private companies	3
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.	Health Technology
Cell Genesys, Inc. Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.	Health Technology
Elitra Pharmaceuticals, Inc. Elitra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Elitra Pharmaceuticals, Inc. used to develop pharmaceutical products. The company employed proprietary methods for gene analysis and anti-microbial drug discovery. It used to develop technology to miniaturize anti-microbial drug screens. It was also engaged in the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. The company was founded in 1997 and was headquartered in San Diego, CA	Health Technology

See company connections